Why pharmaceutical pricing needs reform

The NHS expenditure on pharmaceuticals, especially in hospital settings, has outpaced the expenditure on other healthcare services. There is a question on whether this allocation of money is the most efficient in terms of saving lives. Huseyin Naci, Peter Murphy, Beth Woods, James Lomas, Jinru Wei and Irene Papanicolas argue that the way the National Institute for Health and Care Excellence (NICE) calculates the cost-benefit analysis for new drugs should be more transparent, taking into consideration those who will lose out due to reduced resources for other treatments.